Catalio Capital Management, LP Ascendis Pharma A/S Transaction History
Catalio Capital Management, LP
- $457 Billion
- Q4 2024
A detailed history of Catalio Capital Management, LP transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Catalio Capital Management, LP holds 215,587 shares of ASND stock, worth $31.1 Million. This represents 6.49% of its overall portfolio holdings.
Number of Shares
215,587Holding current value
$31.1 Million% of portfolio
6.49%Shares
1 transactions
Others Institutions Holding ASND
# of Institutions
236Shares Held
59.6MCall Options Held
108KPut Options Held
234K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.46 Billion22.55% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.53MShares$797 Million3.52% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.1MShares$735 Million10.24% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.45MShares$641 Million0.98% of portfolio
-
Janus Henderson Group PLC London, X04.38MShares$631 Million0.32% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $8.04B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...